Instituto de Investigación Sanitaria Gregorio Marañón-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2022

  1. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline

    Expert Opinion on Investigational Drugs

  2. Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome

    Cardiovascular research, Vol. 118, Núm. 4, pp. 1046-1060

2021

  1. A rare HCN4 variant with combined sinus bradycardia, left atrial dilatation, and hypertrabeculation/left ventricular noncompaction phenotype

    Revista Espanola de Cardiologia, Vol. 74, Núm. 9, pp. 781-789

  2. Cardiovascular Medications

    Sex Differences in Cardiac Diseases: Pathophysiology, Presentation, Diagnosis and Management (Elsevier), pp. 597-642

  3. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC

    Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 438-448

2020

  1. The p.P888L SAP97 polymorphism increases the transient outward current (Ito,f) and abbreviates the action potential duration and the QT interval

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. New potassium binders reduce the risk of hyperkalaemia in patients treated with renin-angiotensin-aldosterone system inhibitors

    European heart journal. Cardiovascular pharmacotherapy

2017

  1. Future drug discovery in renin-angiotensin-aldosterone system intervention

    Expert Opinion on Drug Discovery, Vol. 12, Núm. 8, pp. 827-848

2016

  1. Vascular and central activation of peroxisome proliferator-activated receptor-β attenuates angiotensin II-induced hypertension: Role of RGS-5

    Journal of Pharmacology and Experimental Therapeutics, Vol. 358, Núm. 1, pp. 151-163

2013

  1. Chronic atrial fibrillation up-regulates β1-Adrenoceptors affecting repolarizing currents and action potential duration

    Cardiovascular Research, Vol. 97, Núm. 2, pp. 379-388